Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 16/20 | 0.87 |
| ▸ | NPC1 | O15118 | 14/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.87 |
| ▸ | MEN1 | O00255 | 12/20 | 0.87 |
| ▸ | MAPT | P10636 | 8/20 | 0.87 |
| ▸ | GAA | P10253 | 7/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.73 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.73 |
| ▸ | RELA | Q04206 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18029503 | 0.93 | RAB9A (1.00) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL29858646 | 0.85 | RAB9A (1.00) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL3407963 | 0.85 | RAB9A (1.00) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL24358168 | 0.82 | RAB9A (0.72) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL30745766 | 0.82 | RAB9A (0.72) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL16137473 | 0.82 | RAB9A (0.82) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL16137398 | 0.80 | RAB9A (0.85) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL16137396 | 0.77 | NPC1 (0.79) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL24358063 | 0.76 | NPC1 (0.75) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL29601192 | 0.76 | NPC1 (0.75) | RAB9ANPC1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | disclosed |
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | disclosed |
| EP-3030657-B1 | LIGASE E3 RNF185 INHIBITORS AND USES THEREOF | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2018-07-18 | — | — | EP | disclosed |
| US-9987256-B2 | CFTR corrector for the treatment of genetic disorders affecting striated muscle | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-06-05 | — | — | US | disclosed |
| US-9987256-B2 | CFTR corrector for the treatment of genetic disorders affecting striated muscle | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-06-05 | — | — | US | disclosed |
| US-20160194644-A1 | LIGASE E3 RNF185 INHIBITORS AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2016-07-07 | — | — | US | disclosed |
| EP-3030657-A1 | LIGASE E3 RNF185 INHIBITORS AND USES THEREOF | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2016-06-15 | — | — | EP | disclosed |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2015-11-19 | — | — | US | disclosed |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2015-11-19 | — | — | US | disclosed |
| WO-2015018831-A1 | LIGASE E3 RNF185 INHIBITORS AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-02-12 | — | — | WO | disclosed |
| EP-2835423-A1 | Ligase E3 RNF185 inhibitors and uses thereof | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2015-02-11 | — | — | EP | disclosed |
| WO-2014086687-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | RAB9A 687/4885NPC1 959/4885KMT2A 3813/4885 |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | RAB9A 789/4885NPC1 1006/4885KMT2A 3932/4885 |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | CFTR, ABCC5, QPCT | RAB9A 400/4885NPC1 115/4885KMT2A 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.